Literature DB >> 1672507

Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons.

G M Graham1, L Guarini, T A Moulton, S Datta, S Ferrone, P Giacomini, R S Kerbel, P B Fisher.   

Abstract

Administration of interferon as a single therapeutic regimen in cancer patients with various neoplasias has had only limited efficacy in ameliorating the negative clinical course of their disease. In the present study, we have evaluated the effect of recombinant human fibroblast (IFN beta) and immune (IFN gamma) interferon, alone and in combination, on growth, differentiation and the expression of class I and II histocompatibility locus antigens (HLA) and melanoma-associated antigens on the human melanoma cell line H0-1. The effect of combinations of interferons on the antigenic profile of human melanoma cells displaying different organ colonization and spontaneous metastatic potential in athymic nude mice was also determined. H0-1 cells were more sensitive to the antiproliferative activity of IFN beta than to IFN gamma and the combination of interferons resulted in a potentiation of growth suppression. The antiproliferative effect of both interferons was greater in later-passage than in earlier-passage H0-1 cells, possibly reflecting alterations in the evolving tumor cell population as a result of long-term in vitro propagation and/or the selective outgrowth of cells with an increased growth rate. The enhanced growth suppression observed in H0-1 cells treated with the combination of IFN beta plus IFN gamma was not associated with a significant increase in the level of melanin, a marker of melanoma differentiation, above that observed with either interferon used alone. IFN beta and IFN gamma differentially modulated the expression of class I and II HLA and melanoma-associated antigens in H0-1 cells and a series of melanoma cells with different organ colonization and metastatic potential, including MeWo, MeM 50-10, MeM 50-17, 3S5 and 70W. No consistent potentiation or antagonism in the expression of any specific antigen was observed in any of the melanoma cell lines exposed to the combination of interferons. The present study demonstrates that the combination of IFN beta plus IFN gamma can potentiate growth suppression in H0-1 human melanoma cells and that this effect is not associated with an increase in differentiation or a potentiation in antigenic modulation. In addition, no direct correlation between the expression of any specific antigen or its modulation by IFN beta or IFN gamma, alone or in combination, and organ colonization and metastatic potential in nude mice was observed in the different melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672507     DOI: 10.1007/bf01741333

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  47 in total

Review 1.  Interferon therapy in cancer: from imaginon to interferon.

Authors:  D Goldstein; J Laszlo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

2.  Synergistic antiproliferative effect of recombinant alpha-interferons with recombinant gamma-interferon.

Authors:  H R Hubbell; J A Craft; P J Leibowitz; D H Gillespie
Journal:  J Biol Response Mod       Date:  1987-04

3.  Isolation and characterization of spontaneous wheat germ agglutinin-resistant human melanoma mutants displaying remarkably different metastatic profiles in nude mice.

Authors:  M Ishikawa; J W Dennis; S Man; R S Kerbel
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

4.  Measurement of the effect of interferons on cellular differentiation in murine and human melanoma cells.

Authors:  P B Fisher; A F Miranda; L E Babiss
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

5.  Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons.

Authors:  J W Greiner; J Schlom; S Pestka; J A Langer; P Giacomini; M Kusama; S Ferrone; P B Fisher
Journal:  Pharmacol Ther       Date:  1985       Impact factor: 12.310

6.  Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens.

Authors:  V Quaranta; M A Pellegrino; S Ferrone
Journal:  J Immunol       Date:  1981-02       Impact factor: 5.422

7.  Potentiation of the antiviral and anticellular activities of interferons by mixtures of HuIFN-gamma and HuIFN-alpha or HuIFN-beta.

Authors:  E Oleszak; W E Stewart
Journal:  J Interferon Res       Date:  1985

8.  Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes.

Authors:  M Tsujisaki; M Igarashi; K Sakaguchi; M Eisinger; M Herlyn; S Ferrone
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

9.  Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.

Authors:  P Giacomini; F Veglia; P Cordiali Fei; T Rehle; P G Natali; S Ferrone
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

10.  Expression and modulation by cytokines of the intercellular adhesion molecule-1 (ICAM-1) in human central nervous system tumor cell cultures.

Authors:  L Guarini; M Temponi; J N Bruce; A P Bollon; G J Duigou; T A Moulton; S Ferrone; P B Fisher
Journal:  Int J Cancer       Date:  1990-12-15       Impact factor: 7.396

View more
  4 in total

1.  Identification and cloning of human polynucleotide phosphorylase, hPNPase old-35, in the context of terminal differentiation and cellular senescence.

Authors:  Magdalena Leszczyniecka; Dong-Chul Kang; Devanand Sarkar; Zao-Zhong Su; Matthew Holmes; Kristoffer Valerie; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-09       Impact factor: 11.205

2.  Defining the domains of human polynucleotide phosphorylase (hPNPaseOLD-35) mediating cellular senescence.

Authors:  Devanand Sarkar; Eun Sook Park; Luni Emdad; Aaron Randolph; Kristoffer Valerie; Paul B Fisher
Journal:  Mol Cell Biol       Date:  2005-08       Impact factor: 4.272

3.  Modulation of the antigenic phenotype of human breast carcinoma cells by modifiers of protein kinase C activity and recombinant human interferons.

Authors:  J A Leon; M C Gutierrez; H Jiang; A Estabrook; S Waxman; P B Fisher
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 4.  Targeting tumor invasion: the roles of MDA-9/Syntenin.

Authors:  Timothy P Kegelman; Swadesh K Das; Luni Emdad; Bin Hu; Mitchell E Menezes; Praveen Bhoopathi; Xiang-Yang Wang; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Ther Targets       Date:  2014-09-15       Impact factor: 6.902

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.